Product Name: Carfilzomib
CAS No: 868540-17-4
Molar Mass: 719.91
Chemical Formula: C40H57N5O7
Synonyms: Kyprolis, PR 171
Storage: Store at -20℃
Sequence: XLFL
Target: peptide epoxyketone class proteasome
Application: Carfilzomib (CAS: 868540-17-4) is a proteasome inhibitor used primarily in the treatment of multiple myeloma, a type of cancer affecting plasma cells in the bone marrow. Its mechanism of action involves irreversibly binding to and inhibiting the chymotrypsin-like activity of the 20S proteasome, leading to the accumulation of misfolded proteins and ultimately inducing apoptosis in cancer cells. Carfilzomib is particularly effective in patients who have relapsed or become refractory to other treatment options. In pharmaceutical chemistry, the design and synthesis of carfilzomib and related proteasome inhibitors represent significant advancements in cancer therapy, offering targeted approaches to disrupt proteasome function and combat tumor progression. Moreover, ongoing research focuses on optimizing carfilzomib’s pharmacokinetic properties and exploring its potential in combination therapies for various malignancies, highlighting its importance in the field of oncology.
